Juul Labs suffers 23% revenue drop in Q1 2022

Jul.21.2022
Juul Labs suffers 23% revenue drop in Q1 2022
Juul Labs Inc. reported a 23% revenue drop and $28 million loss in Q1 2022, amid pressure from government regulators.

According to insiders, Juul Labs Inc. suffered a loss in the first quarter of 2022, with revenue dropping by 23% compared to the previous year. The company has been trying to regain public trust during the government's crackdown on youth vaping.


According to sources, Juul presented financial data during its search for rescue financing. As of March 31st, Juul generated revenue of $259 million in the first quarter, with a pre-adjustment loss of $28 million due to interest, taxes, depreciation, and amortization. In the same period last year, the company reported revenue of $29 million.


Due to regulatory efforts to crack down on underage e-cigarette use, Juul is facing increasing sales pressure. In June, the FDA banned the placement of Juul products on shelves in the United States, citing a lack of evidence demonstrating the overall safety of the company's products and noting Juul's disproportionate role in the rise of youth e-cigarette use. Juul then won an emergency court order, temporarily halting the decision and allowing the company to continue selling its products. Juul is also facing a series of consumer lawsuits that could result in millions of dollars in damages.


The company is currently attempting to raise funds in order to gain some breathing room prior to several repayment deadlines.


According to unnamed sources, Juul currently has $323 million in cash on hand as of the first quarter, which is lower than the $428 million they had during the same period last year. Their total debt amounts to around $2.15 billion, which includes a $394 million term loan due in August 2023 and approximately $1.7 billion in "physically settled securities" notes due in 2025 that allow the company to defer interest payments.


Consideration of bankruptcy.


In addition to considering financing options, the company has been exploring various alternatives, including filing for bankruptcy. According to a Bloomberg report earlier this month, Kirkland & Ellis and Alvarez & Marsal have been providing Juul with litigation and restructuring advice.


The potential ban by the FDA is part of a long-running movement by the government to control electronic cigarette manufacturers. Flavorings such as mango and crème brûlée have helped Juul's founders become billionaires, and seem to be aimed at attracting young customers, despite the company's claims that its products offer a safer way for smokers to consume nicotine.


In 2019, Juul ceased the sale of most flavors, and the following year, the FDA prohibited the entry of sweet and fruity flavors into the market.


A spokesperson for Juul has stated that the company is exploring alternative financing options in light of ongoing FDA scrutiny and has yet to decide on any particular course of action. The statement also affirms the company's commitment to providing their product to adult consumers seeking an alternative to traditional cigarettes.


Translate into standard journalistic English:



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Global Tobacco Control Faces Regional Adaptation Test as Nicotine Markets Evolve, Asian Specialist Says
Global Tobacco Control Faces Regional Adaptation Test as Nicotine Markets Evolve, Asian Specialist Says
As e-cigarettes, heated tobacco products and nicotine pouches expand across global markets, a central question is gaining urgency: can tobacco control rely on a universal policy model? In an interview with 2Firsts, Asian public health and addiction medicine specialist Dr. Rashidi Mohamed bin Pakri Mohamed says Western experience remains relevant, but policies must be adapted to local culture, healthcare systems, enforcement capacity, illicit markets and clinical evidence.
Jul.08
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary Resigns After Opposing Trump Administration’s Flavored Vape Push
FDA Commissioner Marty Makary resigned on May 12 after opposing the Trump administration’s push to authorize fruit-flavored vaping products, according to reporting by The New York Times. Makary reportedly objected over concerns that flavored vapes could attract young people and refused to support broader approvals.
News
May.13
PMI to Launch IQOS in Argentina by End-2026 After Regulatory Shift, Targeting About 7 Million Smokers
PMI to Launch IQOS in Argentina by End-2026 After Regulatory Shift, Targeting About 7 Million Smokers
Philip Morris International (PMI) has confirmed plans to bring its IQOS heated tobacco device to Argentina by the end of 2026, after the Argentine government lifted long-standing restrictions and created a regulatory framework for heated tobacco, e-cigarettes and nicotine pouches.
News
Jun.26 by 2Firsts Perspectives
Supreme Vape Revenue Rises 15% Despite UK Disposable Vape Ban
Supreme Vape Revenue Rises 15% Despite UK Disposable Vape Ban
UK consumer goods group Supreme said its vaping revenue rose 15% to £148.1 million in the year to March 31, 2026, despite the UK disposable vape ban taking effect during the period, while the company identified the Vaping Products Duty due in October as the next major industry milestone.
Regulations
Jul.03 by 2Firsts Perspectives
Illegal Vape Retailers in UK Could Face 12-Month Shutdowns
Illegal Vape Retailers in UK Could Face 12-Month Shutdowns
The UK government plans to expand police and trading standards powers by extending closure orders for shops selling illegal vapes and cigarettes from a maximum of six months to 12 months, in a crackdown on organised crime on high streets.
Jun.12
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14